Colorado judge blocks 70% price cap on Amgen's Enbrel, citing potential economic injury

A U.S. District Court in Colorado issued a preliminary injunction that stops a state‑imposed 70% price cap on Amgen's autoimmune drug Enbrel. The ruling was made by Judge Daniel Domenico, who granted Amgen's request for relief.

The court found that the steep price reduction could cause economic injury to Amgen, arguing that such a cap would interfere with the company's ability to recoup development costs and maintain supply.

The decision represents a setback for Colorado's effort to control drug costs and may influence how other states approach price‑cap legislation, while providing Amgen a temporary reprieve from the proposed pricing restriction.